Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Stephen R. Marder |
Documentos disponibles escritos por este autor (7)
Refinar búsquedaCase reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation / Stephen R. Marder en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 4 (Abril)
Título : Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation Tipo de documento: texto impreso Autores: Stephen R. Marder, Autor ; Sebastian Sorsaburu, Autor ; Eduardo Dunayevich, Autor Fecha de publicación: 2022 Artículo en la página: pp. 433-441 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Benzodiazepinas, Trastorno bipolar, Agitación psicomotora, Esquizofrenia. Resumen: Agitation is a medical emergency with increased risk for poor outcome. Successful treatment often requires intramuscular (IM) psychotropics. Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented. Link: ./index.php?lvl=notice_display&id=28171
in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 4 (Abril) . - pp. 433-441[artículo] Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation [texto impreso] / Stephen R. Marder, Autor ; Sebastian Sorsaburu, Autor ; Eduardo Dunayevich, Autor . - 2022 . - pp. 433-441.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 4 (Abril) . - pp. 433-441
Palabras clave: Antipsicóticos, Benzodiazepinas, Trastorno bipolar, Agitación psicomotora, Esquizofrenia. Resumen: Agitation is a medical emergency with increased risk for poor outcome. Successful treatment often requires intramuscular (IM) psychotropics. Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented. Link: ./index.php?lvl=notice_display&id=28171
Título : Clozapine and risperidone in moderately refractory schizophrenia : A 6-Month randomized double-blind comparison Tipo de documento: texto impreso Autores: Nina R. Schooler, Autor ; Stephen R. Marder, Autor ; K. N. R. Chengappa, Autor Fecha de publicación: 2020 Artículo en la página: pp. 628–634 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Clozapina, Administración de medicamentos, Resistencia al medicamento, Trastornos psicóticos, Risperidona, Esquizofrenia. Resumen: Clozapine remains the only medication indicated for refractory schizophrenia. As new antipsychotic drugs become available, their efficacy compared to clozapine, particularly in moderately ill patients, is of great clinical interest. Link: ./index.php?lvl=notice_display&id=21737
in The Journal of Clinical Psychiatry > Año 2016 - Vol.77 - No.5 (Mayo) . - pp. 628–634[artículo] Clozapine and risperidone in moderately refractory schizophrenia : A 6-Month randomized double-blind comparison [texto impreso] / Nina R. Schooler, Autor ; Stephen R. Marder, Autor ; K. N. R. Chengappa, Autor . - 2020 . - pp. 628–634.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2016 - Vol.77 - No.5 (Mayo) . - pp. 628–634
Palabras clave: Clozapina, Administración de medicamentos, Resistencia al medicamento, Trastornos psicóticos, Risperidona, Esquizofrenia. Resumen: Clozapine remains the only medication indicated for refractory schizophrenia. As new antipsychotic drugs become available, their efficacy compared to clozapine, particularly in moderately ill patients, is of great clinical interest. Link: ./index.php?lvl=notice_display&id=21737
Título : Defining and measuring negative symptoms of schizophrenia in clinical trials Tipo de documento: texto impreso Autores: Stephen R. Marder, Autor ; Brian W. Kirkpatrick, Autor Fecha de publicación: 2021 Artículo en la página: pp. 737-743 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Síntomas negativos de la esquizofrenia Resumen: Recent attention has focused on negative symptoms as a target for new therapeutic approaches including pharmacological agents, medical devices, and psychosocial treatments. Link: ./index.php?lvl=notice_display&id=26988
in European Neuropsychopharmacology > Año 2014 - Vol. 24 - No.5 (Mayo) . - pp. 737-743[artículo] Defining and measuring negative symptoms of schizophrenia in clinical trials [texto impreso] / Stephen R. Marder, Autor ; Brian W. Kirkpatrick, Autor . - 2021 . - pp. 737-743.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2014 - Vol. 24 - No.5 (Mayo) . - pp. 737-743
Palabras clave: Síntomas negativos de la esquizofrenia Resumen: Recent attention has focused on negative symptoms as a target for new therapeutic approaches including pharmacological agents, medical devices, and psychosocial treatments. Link: ./index.php?lvl=notice_display&id=26988
Título : Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia : Pooled analyses from 3 phase II/III studies Tipo de documento: texto impreso Autores: Stephen R. Marder, Autor ; Wolfang Wolfgang Fleischhacker, Autor ; Willie R. Earley, Autor Fecha de publicación: 2021 Artículo en la página: pp. 127-136 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Cariprazina, Antipsicótico atípico, Esquizofrenia, Receptor de dopamina, Receptor de serotonina 5-HT1a Resumen: Schizophrenia affects various symptom domains, including positive and negative symptoms, mood, and cognition. Cariprazine, a dopamine D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist,... Link: ./index.php?lvl=notice_display&id=26385
in European Neuropsychopharmacology > Año 2019 - Vol. 29 - No. 1 (Enero) . - pp. 127-136[artículo] Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia : Pooled analyses from 3 phase II/III studies [texto impreso] / Stephen R. Marder, Autor ; Wolfang Wolfgang Fleischhacker, Autor ; Willie R. Earley, Autor . - 2021 . - pp. 127-136.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2019 - Vol. 29 - No. 1 (Enero) . - pp. 127-136
Palabras clave: Cariprazina, Antipsicótico atípico, Esquizofrenia, Receptor de dopamina, Receptor de serotonina 5-HT1a Resumen: Schizophrenia affects various symptom domains, including positive and negative symptoms, mood, and cognition. Cariprazine, a dopamine D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist,... Link: ./index.php?lvl=notice_display&id=26385 
Título : A long-term, open-label study of valbenazine for tardive dyskinesia Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor Fecha de publicación: 2022 Artículo en la página: pp. 345 - 353 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341
in CNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353[artículo] A long-term, open-label study of valbenazine for tardive dyskinesia [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor . - 2022 . - pp. 345 - 353.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in CNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353
Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341 Permalink
Permalink
